NCT05041842
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Endocrine (Hormone Therapy, Tyrosine-Kinase Inhibitor, Therapeutic antibody
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes:
Exclusions: Patients with leptomeningeal disease; Patients with previous treatment of a tyrosine kinase inhibitor (e.g. Tukysa/tucatinib, Nerlynx/neratinib, Tykerb/lapatinib)
https://ClinicalTrials.gov/show/NCT05041842